A phase I trial (NCT01644968) analysed the toxicity of the intravenous administration of three doses of 9B12 murine agonistic anti-human OX40 mAb in advanced stage solid cancer (melanoma, renal, urethral, and prostate cancers) patients (n = 30), with 12 patients having regression of at least one metastatic lesion after a single course of treatment [234]. The gene discussed is TNFRSF4; the disease is prostate cancer.